Semaglutide 2mg Dose: Where It Sits in Wegovy's Titration Schedule

Why 2mg doesn't appear on any Wegovy prescription

The titration schedule for Wegovy is set by Novo Nordisk and approved by the MHRA. It starts at 0.25mg (a tolerability step designed to let your system adjust gradually) then moves through 0.5mg, 1mg and 1.7mg before reaching 2.4mg as the standard maintenance dose. The MHRA's approval of a 7.2mg pen in April 2026 added a higher ceiling, but the intermediate steps remain unchanged. There is no 2mg rung because the clinical programme was built around those specific doses; the gap between 1.7mg and 2.4mg reflects where the trial evidence lies.

It is worth knowing that Rybelsus (the oral semaglutide tablet licensed for type 2 diabetes) has its own entirely separate dose range of 3mg, 7mg and 14mg. Those numbers belong to a diabetes product, not a weight-loss one, and they should never be treated as part of the Wegovy ladder. If you have read about 3mg semaglutide in a weight-loss context, that framing is incorrect. The NHS medicines page on semaglutide sets out the licensed uses clearly, and it is a useful first port of call if you want to check which product applies to your situation.

The practical upshot: if someone offers you a 2mg semaglutide dose for weight loss, it does not correspond to any licensed UK product schedule. That should prompt a question, not a purchase.

The decision the prescriber is actually weighing at each dose step

Titration is not simply climbing a ladder rung by rung. At each step, the prescriber is balancing how well you are tolerating the current dose against whether it is producing meaningful results. The 1mg step, for instance, is where many people notice appetite changes becoming more consistent. The 1.7mg step sits just below maintenance and is useful if 2.4mg causes side effects that do not settle.

Understanding the 1mg semaglutide dose in context helps: it is not a weak dose that needs rushing past, for some people it is the ceiling their prescriber holds them at because the benefit-to-tolerability balance is right there. Others move comfortably to 2.4mg and beyond. That is the nature of individual clinical assessment.

What the prescriber is not doing is guessing. Each decision is anchored in how you have responded so far, any reported side effects, and whether weight loss is progressing in line with expectations. The STEP 1 trial, published in the New England Journal of Medicine, showed an average weight loss of around 15% at 2.4mg over 68 weeks, but that average emerged from a population with a wide range of individual responses. Your trajectory is the data that matters to your prescriber.

Side effects that can influence dose decisions around the 1.7mg–2.4mg range

Gastrointestinal effects (nausea, loose stools, reduced appetite to the point of not eating enough) are most common after starting a new dose or moving up to the next one. They typically ease within a couple of weeks as the body adjusts. The 1.7mg step exists partly because some people find the jump straight to 2.4mg too much too quickly; staying at 1.7mg for an additional four weeks before moving up is a legitimate clinical choice, not a failure.

Staying well hydrated and eating protein-adequate meals in smaller amounts tends to help, though specific advice on managing side effects at any particular dose should come from your prescriber or the Patient Information Leaflet for your pen. The NHS patient-level guidance on semaglutide on the NHS website covers what to expect and when to seek medical attention, it is worth reading before or shortly after starting treatment.

One practical note: Wegovy pens are stored in the fridge, but keeping them in the door rather than the back shelf helps avoid the temperature drops that happen when a drawer is opened and closed repeatedly. That kind of routine detail is the sort of thing that makes consistent weekly dosing easier to maintain long term.

If you are thinking about starting semaglutide for weight loss or want to understand how the full dose range maps to your situation, exploring Wegovy's dose structure in full is a sensible next step. And if cost is part of the equation, a transparent overview of weight-loss treatment options can help you see what the private route actually involves before you decide.

What this means if you are considering semaglutide for weight loss

Semaglutide for weight management is a prescription-only medicine. The dose you start on, the pace at which you titrate, and the ceiling your prescriber sets are all decisions made after reviewing your medical history, weight, BMI and any relevant conditions, and if you want a clear overview of how those steps work, our semaglutide dose guide lays out the full picture. No legitimate service lets you pick your own dose from a menu.

Eligibility for Wegovy broadly covers adults with a BMI of 30 or above, or 27 and above alongside a weight-related health condition such as high blood pressure, high cholesterol or type 2 diabetes. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. But a number alone never settles the question, the full picture does. You can read about the wider context of how different semaglutide doses are experienced in practice to get a sense of what treatment looks like for real patients.

At nume, every consultation is reviewed by a GPhC-registered Independent Prescriber, a real clinician reading your answers, not an automated system. If you are clinically suitable and approved before midday on a working day, your treatment is dispatched that day, arriving free the next working day by tracked DPD delivery in plain packaging. Our clinical team profile at the prescribers page gives you more on who oversees that process.

If you have questions that are not answered here, our FAQs cover a wide range of practical points about treatment, eligibility and what to expect. When you are ready to take the next step, check your eligibility with a free consultation and a prescriber will take it from there.